Telomir Pharmaceuticals, Common Stock Current Valuation
| TELO Stock | 4.91 0.03 0.61% |
Valuation analysis of Telomir Pharmaceuticals, helps investors to measure Telomir Pharmaceuticals,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 17th of December 2024, Enterprise Value Over EBITDA is likely to drop to -19.05. In addition to that, Enterprise Value Multiple is likely to drop to -19.05. Fundamental drivers impacting Telomir Pharmaceuticals,'s valuation include:
Price Book 332.4742 | Enterprise Value 147.1 M |
Overvalued
Today
Please note that Telomir Pharmaceuticals,'s price fluctuation is very risky at this time. Calculation of the real value of Telomir Pharmaceuticals, is based on 3 months time horizon. Increasing Telomir Pharmaceuticals,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Telomir Pharmaceuticals, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telomir Stock. However, Telomir Pharmaceuticals,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.91 | Real 4.29 | Hype 4.91 |
The intrinsic value of Telomir Pharmaceuticals,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telomir Pharmaceuticals,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telomir Pharmaceuticals, Common helps investors to forecast how Telomir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telomir Pharmaceuticals, more accurately as focusing exclusively on Telomir Pharmaceuticals,'s fundamentals will not take into account other important factors: Telomir Pharmaceuticals, Common Company Current Valuation Analysis
Telomir Pharmaceuticals,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Telomir Pharmaceuticals, Current Valuation | 147.08 M |
Most of Telomir Pharmaceuticals,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telomir Pharmaceuticals, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Telomir Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Telomir Pharmaceuticals, is extremely important. It helps to project a fair market value of Telomir Stock properly, considering its historical fundamentals such as Current Valuation. Since Telomir Pharmaceuticals,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Telomir Pharmaceuticals,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Telomir Pharmaceuticals,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Telomir Pharmaceuticals, Common has a Current Valuation of 147.08 M. This is 98.98% lower than that of the Pharmaceuticals sector and 96.83% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.12% higher than that of the company.
Telomir Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telomir Pharmaceuticals,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telomir Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Telomir Pharmaceuticals, by comparing valuation metrics of similar companies.Telomir Pharmaceuticals, is currently under evaluation in current valuation category among its peers.
Telomir Pharmaceuticals, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Telomir Pharmaceuticals,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Telomir Pharmaceuticals,'s managers, analysts, and investors.Environmental | Governance | Social |
Telomir Fundamentals
| Return On Equity | -17.53 | ||||
| Return On Asset | -2.05 | ||||
| Current Valuation | 147.08 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Shares Owned By Insiders | 42.66 % | ||||
| Shares Owned By Institutions | 6.90 % | ||||
| Number Of Shares Shorted | 650.6 K | ||||
| Price To Book | 332.47 X | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (13.07 M) | ||||
| Total Debt | 101 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (3.86 M) | ||||
| Short Ratio | 5.77 X | ||||
| Earnings Per Share | (0.78) X | ||||
| Target Price | 12.15 | ||||
| Market Capitalization | 146.98 M | ||||
| Total Asset | 4.77 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | (900.34 K) | ||||
| Net Asset | 4.77 M |
About Telomir Pharmaceuticals, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telomir Pharmaceuticals, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telomir Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telomir Pharmaceuticals, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Telomir Pharmaceuticals,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Moving against Telomir Stock
| 0.64 | ALVO | Alvotech | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb | PairCorr |
| 0.56 | GILD | Gilead Sciences | PairCorr |
| 0.46 | XAIR | Beyond Air | PairCorr |
| 0.39 | CAH | Cardinal Health | PairCorr |
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Telomir Pharmaceuticals, Piotroski F Score and Telomir Pharmaceuticals, Altman Z Score analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.